These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1719686)

  • 1. [The clinical use of the prostate-specific antigen in patients with prostatic cancer].
    Matveev BP; Sokolov AV; Bukharkin BV; Ledian KM; Tilk AE; Makarova GV
    Urol Nefrol (Mosk); 1991; (4):8-12. PubMed ID: 1719686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostatic specific antigen for detection and monitoring of prostatic cancer].
    Gofrit O; Pode D; Gez E; Pfau A; Roizman I; Lifshitz Y; Barak V
    Harefuah; 1992 Mar; 122(6):345-8, 408. PubMed ID: 1374729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
    Kabalin JN
    Geriatrics; 1992 Sep; 47(9):26-32. PubMed ID: 1380941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate].
    Lo Cigno M; Montanari F; Bercovich E; Soli M; Emili E; Dal Pozzo C; Platè L; Bianchi D
    Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):29-36. PubMed ID: 2469127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
    Morote Robles J; de Torres Mateos JA
    Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.
    Wang TY; Kawaguchi TP
    Ann Clin Lab Sci; 1986; 16(6):461-6. PubMed ID: 3800301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
    Tanaka Y; Aoyama H; Momose H; Ono T; Samma S; Tanaka N; Akiyama T; Tani Y; Masuda Y; Matsuki H; Tani M; Tanaka M
    Hinyokika Kiyo; 2001 Jan; 47(1):11-4. PubMed ID: 11235214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
    Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
    Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
    Barak M; Mecz Y; Lurie A; Gruener N
    J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
    Arai T; Fujita K; Fujime M; Irimura T
    Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.